SRR1516096
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- MYOGENESIS+0.280
- APICAL_JUNCTION+0.250
- HEDGEHOG_SIGNALING+0.220
- WNT_BETA_CATENIN_SIGNALING+0.190
- TNFA_SIGNALING_VIA_NFKB+0.150
- TGF_BETA_SIGNALING+0.140
- MITOTIC_SPINDLE+0.130
- G2M_CHECKPOINT+0.110
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
- MYC_TARGETS_V1-0.330
- MYC_TARGETS_V2-0.330
- FATTY_ACID_METABOLISM-0.280
- ALLOGRAFT_REJECTION-0.270
- ADIPOGENESIS-0.260
- PEROXISOME-0.260
- BILE_ACID_METABOLISM-0.230
- ESTROGEN_RESPONSE_LATE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR27320698 | — | — | 0.826 |
| 2 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.807 |
| 3 | 66e5440a-6b08-43cc-b007-82ac3f5221d1 | — | — | 0.789 |
| 4 | SRR8613792 | — | D | 0.775 |
| 5 | SRR6013521 | — | cohortA1 | 0.765 |
| 6 | 20040107.TNBC | — | E | 0.761 |
| 7 | MBCProject_0044_T1_RNA | — | A | 0.761 |
| 8 | TCGA-D8-A27H-01A-11R-A16F-07 | — | E | 0.761 |
| 9 | C3L-02661 | — | cohortA1 | 0.756 |
| 10 | TCGA-55-8614-01A-11R-2403-07 | — | cohortSQ1 | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.040 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |